Table 2 Uptake of regular monitoring for patients on ART at different time points of treatment follow-up

Assefa, 2011 [30]

6 months

Health center: 5072/6197

Hospital: 24,821/31,269

Not report (NR)

54%

NR

Not stated

Not stated

Number of patients received immunological monitoring with CD4 count documented was not reported. Data (proportion of patient monitored) was not reported separately for each level of care

12 months

Health center: 3042/4022

Hospital: 17,037/23,039

NR

51%

24 months

Health center 650/856

Hospital : 4419/6595

NR

51%

Bedelu, 2007 [17]

12 months

Health clinic: 482/595

Hospital: 289/430

Health clinic: 296/482 (61.4%)

Hospital: 41/289 (14.2%)

Health clinic: 348/482 (72.2%)

Hospital: 81/289 (28%)

NR

Not stated

Not stated

Boulle, 2010 [19]

1 year

4512

3932/4512 (87%)

3823/4512 (85%)

NR

CD4 and VL provided 6-monthly after staring ART

Not stated

VL: NucliScens EasyQHIV-1 assay

CD4: single-platform panleucogating method

Type of blood used not reported

2 years

2561

2198/2561 (86%)

2108/2561 (82%)

3 years

1235

983/1235 (79.6%)

931/1235 (75.4%)

4 years

458

351/458 (76.6%)

341/458 (74.5%)

5 years

191

148/191 (77.5%)

127/191 (66.5%)

Brennan, 2011 [16]

12 months

Hospital : 1958/2079

Primary health care: 681/693

Hospital: 1774/1958 (90.6%)

PHC 676/681 (99.2%)

PHC: 95%

Hospital: 81%

Clinical monitor performed every 2 months by nurse at PHC; 6 monthly by doctor at hospital

CD4 and VL test measured every 6 month

Not stated

Inconsistency in data on % patients with CD4 and VL data available between text and table. Number of patients with 12 months CD4 count available not reported

Fatti, 2010 [41]

12 months

11,960

6725 (56.2%)

NR

Patients attend monthly clinical checks

CD4 count and VL monitored 6 monthly for patient on treatment by SA NHL services

Off-site except for large hospital

Data (n/N) on proportion of patient received and had VL available was reported for all level of care

24 months

4029

2525 (62.6%)

36 months

545

342 (62.8%)

Fairall, 2012 [13]

12 months

Primary care: 2823/3029

Hospital: 2981/3202

Primary care: 2582/2823 (91.5%)

Hospital: 2656/2981 (89.1%)

NR

NR

Not stated

Not stated

Hansudewe-chakul, 2012 [15]

12, 24, 36, 48 months (VL data available at baseline and at least 1 follow-up)

Community hospital: 154

Tertiary hospital : 133

CH: 22/154 (14.3%)

TH: 38/133 (28.6%)

NR

Clinical monitoring using CDC classification;

CD4% assessed 6 monthly, routine VL testing not available. VL measured at 12 month intervals for 48 months

Not stated

No time point specific provided for % patient with VL data available. Scheduled clinic visit 6 monthly at tertiary hospital

Janssen, 2010 [21]

6–12 months

447

193/447 (43.2%)

CD4%: 310/447 (69.3%); CD4: 315/447 (70.5%)

NR

Laboratory tests (CD4, VL, Hemoglobin/albumin) repeated 6 monthly

VL testing at referral hospital (75 km away); other tests at local hospital

Jobanputra, 2014 [26]

12 months

5563

4767/5563 (86%)

NR

NR

VL measured annually using a Generic HIV VL platform (Biocentric)

VL testing at regional virology laboratory

Mutevedzi, 2010 [20]

12 months

2527/3010

758/2527 (30%)

NR

NR

CD4 count and VL measured every 6 months

VL testing at provincial lab

VL measured by Nucli-Sens Easy HIV-1 assay). Type of blood used not report

Rich, 2012 [22]

24 months

926

275/926 (29.7%)

710/926 (76.7%)

NR

CD4 count measured 6 monthly using BD fluorescence-activated cell sorting count system

Not stated

Selke, 2010 [14]

12 months

Intervention: 87

Control: 102

Intervention: 86/87 (99%)

Control: 96/102 (94.1%)

Intervention: 87/87 (100%)

Control: 96/102 (94.1%)

Intervention: 74/87 (85%)

Control: 87/102 (85.3%)

VL and CD4 count obtained at initial and close out research visit. Additional CD4 count at 6 months

Not stated

Shumbusho, 2009 [24]

6 months

217

NR

193/217 (88.9%)

83.4%: side effect screening at all visits (frequency not reported)

CD4 count measured every 6 month using BD FACS Count

District hospital laboratory

12 months

123

NR

104/123 (84.5%)

18 months

43

NR

31/43 (72.1%)

24 months

10

10/10 (100%)

Uzodike, 2015 [18]

Jun 2011

488

407/488 (83.4%)

461/488 (94.5%)

412/488 (84.4%)

CD4 and VL monitored 6 monthly

Not stated

Clinical monitoring carried out monthly by nurses

Dec 2011

466/488 (95.5%)

464/488 (95.1%)

NR

Jun 2012

444/488 (91.0%)

430/488 (88.1%)

381/488 (78%)

Vogt, 2015 [23]

6 months

1250

NR

194/1250 (15.5%)

1250/2145 (58%)

Whole blood collected in EDTA tube for testing by BD Fascount and Partect Cyflow

District hospital laboratory

Data is presented for both hospital and RHCs

12 months

1199

NR

74/1199 (6.2%)

1199/2145 (56%)

Walter, 2014 [12]

6 months

11,243

NR

5859 (52%)

NR

Not stated

Not stated

12 months

8644

5160 (60%)

18 months

6467

4110 (64%)

24 months

4485

3201 (71%)